Skip to content

FAPI PET/MR in the prospective study of predicting the invasive growth direction of pituitary neuroendocrine tumors

FAPI PET/MR in the prospective study of predicting the invasive growth direction of pituitary neuroendocrine tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121095
Enrollment
Unknown
Registered
2026-03-25
Start date
2024-12-30
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PitNETs.

Interventions

Gold Standard:Postoperative follow-up examination, routine blood tests, and enhanced magnetic resonance imaging examination
Index test:FAPI PET/MR local imaging

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathological or clinical diagnosis of pituitary neuroendocrine tumor; 2. Pituitary neuroendocrine tumor Knosp grade II-IV or suspected bone invasion or breach of the sellar diaphragm with surgical indications; 3. Age between 18 and 75 years; 4. No restriction on gender; 5. Voluntary participation and signing of informed consent form.

Exclusion criteria

Exclusion criteria: 1. Contraindications for magnetic resonance examination: functional electronic devices and various stimulators (such as pacemakers, cochlear implants, etc.) implanted in the body; implants made of ferromagnetic materials (such as those containing iron, cobalt, nickel, etc.). Infusion devices implanted in the body, such as insulin or other infusion pumps; 2. Individuals with claustrophobia; 3. Patients unable to lie flat for 30 minutes during clinical assessment; 4. History of severe systemic diseases or mental illnesses affecting the heart, liver, kidneys, brain, blood, immune system, etc. 5. Individuals with fertility plans in the past two years or pregnant women; 6. Currently participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Sensitivity;Specificity;

Secondary

MeasureTime frame
Area Under the Receiver Operating Characteristic Curve;

Countries

China

Contacts

Public ContactLin Shaojian

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

15801782758@126.com+86 21 6437 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026